Red and Blue States Alike Want To Limit AI in Insurance. Trump Wants To Limit the States.

Why It Matters

State AI restrictions could reshape how insurers evaluate claims, affecting costs and patient access, while the federal‑state clash may set a precedent for AI governance nationwide.

Key Takeaways

• States enact AI restrictions for health insurance claims
• Trump order aims to preempt state AI regulations
• Insurers argue regulations hinder innovation and increase costs
• AMA supports transparency, while trade groups seek balanced policies
• Federal preemption faces constitutional challenges

Pulse Analysis

The surge of state‑level AI regulation reflects growing public anxiety about opaque algorithmic decisions in health insurance. Recent polls show two‑thirds of Americans, across party lines, fear AI’s impact on personal data and medical outcomes. Legislators in Arizona, Maryland, Nebraska, Texas and others have enacted statutes requiring human oversight of AI‑generated coverage decisions, aiming to curb rapid claim denials that have sparked lawsuits and media scrutiny. These measures align with the American Medical Association’s call for greater transparency, positioning patient safety at the forefront of the debate.

At the federal level, President Trump’s December executive order seeks to nullify state AI restrictions, framing them as barriers to national competitiveness in the AI race. The order threatens to withhold federal funding from states deemed to impose “excessive” regulations, a move that could trigger constitutional challenges over the separation of powers and the Commerce Clause. Legal scholars argue that preempting state authority without congressional backing is likely untenable, setting up a courtroom showdown that could define the balance of AI governance between Washington and the states.

Health insurers are caught between divergent pressures: state lawmakers demand accountability, while industry groups warn that a fragmented regulatory landscape will divert resources from patient‑centric innovations. Companies like UnitedHealth’s Optum tout AI‑powered prior authorization as a means to reduce administrative friction, yet they must navigate varying state mandates that may require human sign‑off on every algorithmic recommendation. The outcome of this policy tug‑of‑war will influence not only the speed of AI adoption in healthcare but also the broader trajectory of AI regulation across sectors, making it a pivotal issue for policymakers, providers, and consumers alike.